Do Proton Pump Inhibitors Contribute to Weight Gain?

Obesity Surgery

Volumn 25, Issue 6, 2015, Pages 1071-1072

  Syu, Yu Fong ^a   Huang, Hsien Hao ^a,b   Chen, Chih Yen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; RNA 16S;

FEMALE; GENETICS; HUMAN; INTESTINE; MALE; MICROBIOLOGY; MICROFLORA; OBESITY, MORBID; STOMACH BYPASS; WEIGHT REDUCTION;

FEMALE; GASTRIC BYPASS; HUMANS; INTESTINES; MALE; MICROBIOTA; OBESITY, MORBID; PROTON PUMP INHIBITORS; RNA, RIBOSOMAL, 16S; WEIGHT LOSS;

EID: 84937218445     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1659-x     Document Type: Letter

References (4)

1. Ward EK, Schuster DP, Stowers KH, et al. The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2014;24(9):1567–71.
2. Yoshikawa I, Nagato M, Yamasaki M, et al. Long-term treatment with proton pump inhibitor is associated with undesired weight gain. World J Gastroenterol. 2009;15(38):4794–8.
3. Cui GL, Syversen U, Zhao CM, et al. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol. 2001;36(10):1011–5.
4. Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacogenetics in the clinical use of proton pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther. 2003;17(12):1521–8.